

**Oncolytic virus therapy with HSV-1 for hematologic malignancies**

Ryo Ishino,<sup>1,2</sup> Yumi Kawase,<sup>1</sup> Toshio Kitawaki,<sup>1</sup> Naoshi Sugimoto,<sup>3</sup> Maki Oku,<sup>2</sup> Shumpei Uchida,<sup>2</sup> Osamu Imataki,<sup>2</sup> Akihito Matsuoka,<sup>4</sup> Teruhisa Taoka,<sup>4</sup> Kimihiro Kawakami,<sup>5</sup> Toin H. van Kuppevelt,<sup>6</sup> Tomoki Todo,<sup>7</sup> Akifumi Takaori-Kondo,<sup>1</sup> and Norimitsu Kadowaki<sup>2</sup>

<sup>1</sup>Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; <sup>2</sup>Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan; <sup>3</sup>Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan; <sup>4</sup>Division of Internal Medicine, Sakaide City Hospital, Sakaide, Japan; <sup>5</sup>Division of Hematology, Kagawa Prefectural Central Hospital, Takamatsu, Japan; <sup>6</sup>Department of Biochemistry, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands; <sup>7</sup>Division of Innovative Cancer Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Correspondence should be addressed to N.K. ([kado@med.kagawa-u.ac.jp](mailto:kado@med.kagawa-u.ac.jp))

**Corresponding author**

Norimitsu Kadowaki, M.D., Ph.D.

Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan

E-mail: [kado@med.kagawa-u.ac.jp](mailto:kado@med.kagawa-u.ac.jp)

TEL +81-87-891-2143 FAX +81-87-891-2147

Short title: Oncolytic HSV-1 for hematologic malignancies

## **Abstract**

Oncolytic herpes simplex virus type 1 (HSV- 1) has been investigated to expand its application to various malignancies. Because hematopoietic cells are resistant to HSV- 1, its application to hematological malignancies has been rare. Here, we show that the third-generation oncolytic HSV- 1, T-01, infected and killed 18 of 26 human cell lines and 8 of 15 primary cells derived from various lineages of hematological malignancies. T-01 replicated at low levels in the cell lines. Viral entry and the oncolytic effect were positively correlated with the expression level of nectin-1 and to a lesser extent 3-*O*-sulfated heparan sulfate, receptors for glycoprotein D of HSV- 1, on tumor cells. Transfection of nectin-1 into nectin-1-negative tumor cells made them susceptible to T-01. The oncolytic effects did not appear to correlate with the expression or phosphorylation of antiviral molecules in the cGAS-STING and PKR-eIF2 $\alpha$  pathways. In an immunocompetent mouse model, intratumoral injection of T-01 into lymphoma induced regression of injected as well as non-injected contralateral tumors accompanied by abundant infiltration of antigen-specific CD8<sup>+</sup> T cells. These data suggest that intratumoral injection of oncolytic HSV- 1 may be applicable to systemic hematological malignancies. Nectin-1 expression may be the most useful biomarker for optimal efficacy.

**Keywords**

oncolytic virus; HSV-1; hematological malignancies; nectin-1; CD8<sup>+</sup> T cell

## Introduction

Oncolytic virus therapy has been emerging as an important modality of cancer immunotherapy.<sup>1</sup> Notably, oncolytic viruses provoke innate immune responses in the tumor site, thereby converting the immunosuppressive tumor microenvironment to an immune-potentiating one. This leads to activation of intratumor dendritic cells, which engulf the killed tumor cells and present an array of tumor antigens, presumably including neoantigens, in draining lymph nodes. Subsequently, antigen-specific T cells migrate to the inflamed tumor site. Thus, oncolytic virus therapy generates so called Cancer-Immunity Cycle,<sup>2</sup> thereby representing a rational tumor immunotherapy.

Herpes simplex virus type 1 (HSV-1) has been leading the field of oncolytic virus therapy.<sup>3</sup> Mineta et al. generated a second-generation oncolytic HSV-1, G207,<sup>4</sup> which had deletion of the  $\gamma 34.5$  gene and inactivation of ICP6 with a *LacZ* gene insertion, and could replicate only in cancer cells that can complement these mutations. The third-generation G47 $\Delta$  has further deletion of the overlapping region of the  $\alpha 47$  gene and the promoter of the *US11* gene, resulting in increasing the presentation of the peptide-MHC class I complex by tumor cells and also in replicating more efficiently by placing the late *US11* gene under control of the immediate-early  $\alpha 47$  promoter.<sup>5</sup>

Many clinical trials of oncolytic HSV-1 have been conducted.<sup>3</sup> T-VEC (talimogene

laherparepvec), an oncolytic HSV-1 that has deletion of the  $\gamma 34.5$  and  $\alpha 47$  genes and has the gene encoding human granulocyte macrophage colony-stimulating factor, has been approved for advanced melanoma in the USA, Europe, and Australia.<sup>3</sup> We have been conducting clinical trials using G47 $\Delta$  for brain tumors (UMIN000015995, UMIN000011636) and prostate cancer (UMIN000010463), and applications to other types of cancers are expected.

Originally, oncolytic viruses have been invented based on many anecdotal reports that hematological malignancies such as leukemia and lymphoma resolved after viral infection.<sup>6-8</sup> Therefore, oncolytic virus therapy may be particularly effective for hematological malignancies. Several oncolytic viruses have been applied to hematological malignancies in preclinical and clinical trials.<sup>9</sup> However, application of oncolytic HSV-1 to hematological malignancies has been rare,<sup>10,11</sup> because human hematopoietic cells are resistant to HSV-1 replication,<sup>12</sup> and thus oncolytic HSV-1 has been considered unsuitable to treat hematological malignancies.

In this study, we used T-01, an HSV-1 containing modification of the same genes as G47 $\Delta$ ,<sup>13</sup> and examined whether T-01 can infect and kill human hematological tumor cells in vitro. We showed that T-01 does so and that the expression of an HSV-1 receptor, nectin-1, is a determining factor in the oncolytic effect. Furthermore, using

immunocompetent mice, we show that intratumoral injection of T-01 into lymphoma induces tumor-specific immune responses systemically in vivo. This study presents the rationale of applying G47 $\Delta$  for the treatment of hematologic malignancies.

## **Results**

### **T-01 kills human cell lines derived from various lineages of hematological malignancies**

We first examined whether T-01 kills human cell lines derived from hematological malignancies. T-01 exhibited significant cytotoxicity at multiplicity of infection (MOI) 1.0 or less against 18 out of 26 cell lines, including myeloid-, B cell-, and T cell-derived tumors (Table S1 and Figure S1). Figure 1A shows representative cell lines that were susceptible or resistant to T-01. Jurkat and GRANTA-519 cells were significantly killed by T-01 at MOI as low as 0.01, whereas Ramos cells were not killed even at MOI 1.0. ultraviolet (UV)-inactivated T-01 lost cytotoxic activity in Jurkat cells even at a high concentration (MOI 10) (Figure 1B), indicating that intact T-01 is necessary for the cytotoxicity. These data indicate that T-01 kills a substantial fraction of cell lines from human hematological malignancies derived from various lineages.

In addition, Jurkat and GRANTA-519 cells treated with T-01 released ATP (Figure

1C) and HMGB1 (Figure 1D)<sup>14</sup> more than mock-treated cells. These data suggest that hematological tumor cells treated with T-01 undergo immunogenic cell death.

### **A low level of replication of T-01 in hematological tumor cells**

We examined whether replication of T-01 accompanies the cytotoxic activity. We quantified viral replication by real-time PCR of the glycoprotein B (gB) gene of HSV-1 in the T-01-susceptible cell lines. When T-01 was added at MOI 0.1, the copy number of the gB gene increased more than 1,000 times in 24 hours in Vero cells as expected (Figure 2A). In contrast, only low levels of increase or no increase were detected in the T-01-susceptible cell lines (Figure 2A). We added a viral DNA polymerase inhibitor acyclovir to examine whether the low levels of replication contribute to the cytotoxic activity of T-01. Acyclovir at 10  $\mu$ M suppressed the viral replication in Vero cells (Figure 2A) as well as in Jurkat and GRANTA-519 cells (Figure 2B) and attenuated the cytotoxic activity of T-01 in these cell lines (Figure 2C). When T-01 was added at MOI 0.1 or 1.0 to Jurkat cells or at MOI 1.0 to GRANTA-519 cells, acyclovir attenuated the cytotoxic effect of T-01 only partially (MOI 0.1 for Jurkat and MOI 1.0 for GRANTA-519) or not at all (MOI 1.0 for Jurkat) (Figure 1C). Such residual cytotoxicity observed at the higher concentrations (MOI 0.1 or 1.0) of T-01 in the presence of acyclovir may be due to

efficient entry of T-01 into these cell lines as shown below (Figure S2A, B). These data suggest that cytotoxic activity accompanying a low level of viral replication or even efficient viral entry alone contributes to the killing of the hematological tumor cell lines by T-01.

### **The expression levels of nectin-1 on the cell lines most correlate with viral entry and cytotoxicity**

We next examined the differences between T-01-susceptible and resistant cell lines. Viral entry was quantified by culturing cells with EGFP-expressing T-01, T-GFP, for a short period (4 hours) to avoid contribution of viral replication. The efficacy of viral entry into cells was variable among the 26 cell lines (Figure S2A, B). Although viral entry to several T-01-susceptible cell lines (SET-2, ATL-43T, Raji, and KMS-12-BM) was low at 4 hours, EGFP-positive cells increased in 24 hours probably due to progression of viral entry and replication (Figure S2Ci). In contrast, almost no increase in EGFP-positive cells was observed in T-01-resistant cell lines (CHRF-288-11, HL-60, Ramos, SR-786, KIS-1, SU-DHL-1, and FL-318) after 24-hour culture, except for HEL cells which were killed with a higher concentration of T-01 (MOI 10, data not shown) (Figure S2Cii). The degrees of viral entry at 4 hours were positively correlated with those of cytotoxicity (Figure 3A).

Thus, we examined whether the expression levels of HSV-1 glycoprotein D (gD) receptors (nectin-1,<sup>15</sup> herpes viral entry mediator [HVEM],<sup>16</sup> and 3-*O*-sulfated heparan sulfate [3-OS HS]<sup>17</sup>) and gB receptors (paired immunoglobulin-like type 2 receptor [PILR] $\alpha$ ,<sup>18</sup> non-muscle myosin heavy chain [NMHC]-IIA,<sup>19</sup> and NMHC-IIB<sup>20</sup>) correlated with the cytotoxicity. Lymphocytes in peripheral blood expressed HVEM but not nectin-1, 3-OS HS, or PILR $\alpha$  (Figure S3). Monocytes expressed HVEM, PILR $\alpha$ , and a marginal level of nectin-1, but not 3-OS HS. Nectin-1 (Figure S4A), HVEM (Figure S4B), and 3-OS HS (Figure S4C) were expressed on many of the 26 cell lines at various levels, whereas PILR $\alpha$  was not expressed on 11 cell lines we examined (data not shown). Notably, the expression levels of nectin-1 positively correlated with degrees of viral entry and cytotoxicity (Figure 3B). The only exception was HL-60 (labeled with \* in Figure 3B); although it expressed a high level of nectin-1 (Figure S4A), T-01 did not enter (Figure S2) or kill (Figure S1) HL-60. In contrast to nectin-1, the expression levels of HVEM did not correlate with degrees of viral entry or cytotoxicity (Figure 3C). In addition, three nectin-1<sup>+</sup> HVEM<sup>-</sup> cell lines (SKM-1, MEG-01, and Jurkat) underwent efficient viral entry, whereas two nectin-1<sup>-</sup> HVEM<sup>+</sup> cell lines (CHRF-288-11 and Ramos) did not undergo viral entry (Figure S2). The expression levels of 3-OS HS positively correlated with degrees of viral entry and cytotoxicity (Figure 3D), although to the lesser

extent than those of nectin-1. Two nectin-1<sup>+</sup> cell lines (HuT 102 and RPMI 8226) underwent efficient viral entry (Figure S2A, B) despite the absence of 3-OS HS (Figure S4C). There was no T-01-susceptible cell line that is nectin-1<sup>-</sup> 3-OS HS<sup>+</sup>. These data suggest that nectin-1 plays a dominant role in viral entry, compared to 3-OS HS. NMHC-IIA was expressed in all 14 cell lines examined (Figure S5). NMHC-IIB was expressed in all of them except for THP-1 and RPMI 8226 (Figure S5). Thus, the expression of NMHC-IIA and IIB did not correlate with cytotoxicity.

These data suggest that nectin-1 on hematological tumor cells plays a key role in viral entry and subsequent cytotoxicity and that nectin-1 expression predicts the cytotoxicity of T-01 in hematological tumor cells. Although 3-OS HS may also play a role in viral entry and cytotoxicity, the contribution appears to be less than that of nectin-1.

### **The expression levels of nectin-1 in clinical samples correlate with viral entry and cytotoxicity**

We next examined primary hematological tumor cells, and found that viable cells decreased after treatment with T-01 in 8 of 15 samples (Table S2 and Figure S6). Although we added high concentrations (up to MOI 10) of T-01, UV-inactivation abrogated cytotoxic activity of T-01 even at MOI 10 (Figure 1B), indicating that it is

unlikely that contaminants of viral preparations were responsible for the cytotoxicity at MOI 10 for the clinical samples. All of the 8 T-01-susceptible samples expressed nectin-1 (Figure S6). Of note, all of them were from relapsed patients, whereas none of the 5 samples from untreated patients expressed nectin-1 and were resistant to T-01. Seventeen of 22 additional samples from untreated patients failed to express nectin-1 (data not shown). The expression levels of nectin-1, but not of HVEM, were positively correlated with the degrees of cytotoxicity in clinical samples (Figure 4), as observed in the cell lines. These data suggest that T-01 may be more effective for relapsed hematological malignancies, which frequently express nectin-1, than untreated ones.

### **Viral entry via nectin-1 is functionally important for cytotoxicity**

To examine the functional involvement of nectin-1 in viral entry and cytotoxicity, we knocked down the expression of nectin-1 on Jurkat and THP-1 cells. The knockdown significantly decreased the expression levels of nectin-1 and tended to decrease viral entry, although statistically not significant (Figure 5A). The residual entry may be due to incomplete reduction of nectin-1 expression by shRNA or to the low levels of expression HVEM (THP-1) (Figure S4B) or 3-OS HS (Jurkat and THP-1) (Figure S4C). Conversely, human nectin-1 was transduced into Ramos cells and a mouse T-cell lymphoma cell line

E.G7-ovalbumin (OVA). The overexpression of nectin-1 induced viral entry and cytotoxicity in both cell lines (Figure 5B). These data indicate that the expression of nectin-1 is functionally important for viral entry and the cytotoxic effect of HSV-1 against human and mouse hematological tumor cells.

### **Nectin-1 expression and viral entry are upregulated by epigenetic regulation**

Given that expression of nectin-1 on tumor cells is a key factor for direct cytotoxicity of T-01, we examined whether the expression of nectin-1 can be induced or enhanced by epigenetic regulation, using epigenetic compound library screening. We treated nectin-1<sup>+</sup> cells (Ramos) and nectin-1<sup>low</sup> cells (HEL) with the compounds contained in the library and examined whether expression of nectin-1 was induced or enhanced using flow cytometry (Figure S7A). A DNA methyltransferase inhibitor (decitabine), a class IIa histone deacetylase inhibitor (LMK-235), and three inhibitors (CPI-203, I-BET151, and I-BET726) of Bromodomain and Extra-Terminal motif (BET) family proteins upregulated nectin-1 on Ramos and HEL cells without reducing cell viability substantially (Figure S7A). Another DNA methyltransferase inhibitor, azacitidine, did not upregulate nectin-1 (data not shown). I-BET726 also enhanced nectin-1 expression on nectin-1<sup>low</sup> THP-1 and SYK-11L(+) cells (Figure S7B). I-BET726 significantly

enhanced viral entry into HEL, THP-1, and SYK-11L(+) cells in a dose-dependent manner (Figure S7C). LMK-235 significantly enhanced viral entry into Ramos, HEL, and THP-1 cells in a dose-dependent manner (Figure S7C). Despite the upregulation of nectin-1 on Ramos cells by decitabine (Figure S7A, B), it did not significantly enhance viral entry (Figure S7C) for unknown reasons. These data indicate that nectin-1 expression can be upregulated by epigenetic regulation, leading to enhancement of entry of T-01.

### **Expression and activity of the cGAS-STING pathway in hematological tumor cells**

We next examined whether mechanisms of cellular antiviral responses correlated with the cytotoxicity of T-01. It has been reported that the cytoplasmic DNA sensing cGAS-STING pathway is frequently defective in colorectal cancer,<sup>21</sup> melanoma,<sup>22</sup> and ovarian cancer cells,<sup>23</sup> resulting in susceptibility to oncolytic HSV-1. Thus, we examined whether the expression of cGAS and STING correlated with the susceptibility of the hematological tumor cells to T-01. Five (HuT 102, THP-1, RPMI 8226, ATL-43T, and SYK-11L(+)) of the 9 T-01-susceptible cell lines (labeled in red in Figure S8A) expressed both cGAS and STING, whereas 4 (GRANTA-519, Jurkat, ED-40515(+), and MT-2) of the 9 T-01-susceptible cell lines expressed either of them at low or no levels (cGAS in

Jurkat and STING in GRANTA-519, ED-40515(+), and MT-2). Thus, there was no apparent correlation between susceptibility to T-01 and the presence or absence of cGAS/STING in the hematological tumor cells we examined, although the low expression in several cell lines may contribute to susceptibility to T-01.

We examined whether stimulation with T-01 induces phosphorylation of downstream molecules of STING, TBK1 and IRF3, in three T-01-susceptible cell lines (Figure S8B). TBK1 was constitutively phosphorylated in all the cell lines. After stimulation with T-01, phosphorylation of TBK1 and IRF3 was upregulated in MT-2 (although the expression of STING was low as in Figure S8A) but not in THP-1 and ATL-43T cells (Figure S8B, left panel), possibly due to the highly efficient entry of T-01 into MT-2 (Figure S2A, B). When THP-1 and ATL-43T cells were stimulated with HSV-60,<sup>24</sup> a 60-base pair HSV-1-derived double-stranded DNA oligonucleotide that stimulates the STING-dependent pathway, phosphorylation of TBK1 was upregulated in both cell lines, and that of IRF3 was induced in THP-1 but not in ATL-43T cells (Figure S8B, right panel). These data suggest that pathways leading to phosphorylation of TBK1 and IRF3 are preserved in THP-1 and MT-2 cells, whereas it is suppressed in ATL-43T cells at the level of phosphorylation of IRF3.

Expression levels of mRNA of IFN- $\beta$ , the main antiviral molecule induced by the

cGAS-STING pathway,<sup>25</sup> positively rather than negatively correlated with the cytotoxic effect of T-01 (Figure S9), suggesting that the signaling pathway leading to IFN- $\beta$  induction is at least partially preserved in many cell lines despite the susceptibility to T-01.

Collectively, the expression and activity of the cellular antiviral machinery composed of the cGAS-STING-TBK1-IRF3 axis leading to IFN- $\beta$  induction did not appear to correlate with the susceptibility to T-01 of many hematological tumor cell lines we examined.

### **Expression and activity of the PKR-eIF2 $\alpha$ pathway in hematological tumor cells**

After viral infection, activation of the PKR-eIF2 $\alpha$  pathway blocks viral protein synthesis and thereby restricts viral replication in normal cells.<sup>26</sup> ICP34.5, the product of the  $\gamma$ 34.5 gene of HSV-1, interacts with and redirects protein phosphatase 1 $\alpha$  to dephosphorylate eIF2 $\alpha$ , thus enabling continued protein synthesis despite the presence of activated PKR.<sup>27</sup> Because PKR activation is suppressed in transformed cells with an activated Ras pathway,<sup>28</sup>  $\gamma$ 34.5 gene-deleted HSV-1 is expected to replicate in Ras-activated tumor cells. In addition, even if there is residual activity of PKR, early expression of the Us11 protein blocks phosphorylation of eIF2 $\alpha$ , thereby compensating

for the deletion of the  $\gamma 34.5$  gene.<sup>29</sup> Thus, we examined whether expression and/or activation of the PKR-eIF2 $\alpha$  pathway correlates with the susceptibility of hematological tumor cells. PKR protein was expressed in all the cell lines (Figure S10A). After the addition of T-01, phosphorylation of PKR and eIF2 $\alpha$  was not enhanced in T-01-resistant cell lines (Figure S10B, black labels), consistent with the poor entry of T-01 into these cells up to 24 hours as shown in Figure S2Cii. In contrast, phosphorylation of PKR was enhanced in T-01-susceptible cell lines except for ATL-43T cells (Figure S10B, red labels). Phosphorylation of eIF2 $\alpha$  was enhanced in GRANTA-519, Jurkat, HuT 102, RPMI 8226, and SYK-11L(+) but not in THP-1, ED-40515(+), ATL-43T, or MT-2 cells. Collectively, the expression and activity of the PKR-eIF2 $\alpha$  pathway did not correlate with the susceptibility to T-01 of many hematological tumor cell lines we examined. The reduced phosphorylation of PKR or eIF2 $\alpha$  in several cell lines may contribute to susceptibility to T-01.

#### **Antitumor effects of T-01 in vivo in immunodeficient and immunocompetent mice**

We examined whether the antitumor effect of T-01 is observed in vivo using immunodeficient and immunocompetent mice. We implanted GRANTA-519 or ED-40515(+) cells subcutaneously into SCID Beige mice and injected T-01 intratumorally

(Figure 6A). T-01 exhibited strong antitumor effects on both GRANTA-519 and ED-40515(+) cells (Figure 6B), despite the low levels of T-01 replication in these cell lines in vitro (Figure 2A). These data indicate that the direct cytotoxic effect of T-01 efficiently suppresses the growth of T-01-susceptible cell lines in vivo despite the inefficient viral replication in vitro.

The susceptibility of human nectin-1-transfected mouse cell line E.G7-OVA (E.G7-OVA-nectin-1) to T-01 enabled us to examine the immune-mediated effects of T-01 in vivo using immunocompetent mouse models. We implanted E.G7-OVA-nectin-1 cells subcutaneously into the right and left flanks of C57BL/6 mice and injected T-01 intratumorally only into the right flank tumor (Figure 7A). Tumor growth in T-01-injected as well as non-injected sides was significantly suppressed (Figure 7B). In line with this, OVA-specific CD8<sup>+</sup> T cells were intensely accumulated in both T-01-injected and non-injected tumors to the same extent (Figure 7C). In contrast, OVA-specific CD8<sup>+</sup> T cells did not significantly accumulate in the spleen. These data suggest that tumor-specific CTLs induced in T-01-injected tumors migrate and accumulate into the remote tumor and exhibit antitumor effects on both T-01-injected and non-injected tumors.

## **Discussion**

In this study, we showed that oncolytic HSV-1 has the potential to treat hematological malignancies including T-, B-, and myeloid lineages. The expression of nectin-1 is a decisive factor for the oncolytic effect. Local intratumor injection of HSV-1 induced systemic antitumor immune responses. This study opens the possibility of applying oncolytic HSV-1 to hematological malignancies.

It was reported recently that UV-inactivated, non-replicating HSV-1 activates human NK cells and may be used as an immunological adjuvant to activate donor-derived mononuclear cells in vitro for infusion after allogeneic stem cell transplantation.<sup>30</sup> However, because direct oncolysis by replicating virus is expected to be an integral part of the effect of oncolytic virus therapy, it is important to investigate whether replicating HSV-1 infects and kills hematological tumor cells. Here, we showed that T-01 replicated at low levels even in highly susceptible cell lines such as Jurkat and GRANTA-519 cells. Attenuation of the cytotoxicity by acyclovir suggests that cytotoxic activity accompanying such low levels of viral replication contributed to the killing effects.

It has been reported that the expression of nectin-1 correlates with HSV-1 entry and oncolysis in thyroid cancer,<sup>31</sup> squamous cell carcinoma,<sup>32</sup> and EBV-associated lymphoproliferative disease.<sup>33</sup> However, different studies suggested that other factors such as cellular antiviral responses,<sup>34,35</sup> rather than the expression of nectin-1, determines

the efficacy of oncolytic HSV-1. Thus, the importance of nectin-1 expression in oncolysis remains to be determined. In this study, we showed that the expression of nectin-1 is a critical factor in viral entry and oncolysis, using cell lines, freshly isolated clinical samples, and nectin-1-transfected cells. Intriguingly, all the nectin-1-expressing, HSV-1-susceptible clinical samples were derived from relapsed patients, suggesting that progression of malignant transformation that occurred in relapsed tumors may lead to the expression of nectin-1. Cell line HL-60 was an exception, in that T-01 did not enter the cells despite high levels of nectin-1 expression. Such a cell line may have mutations in nectin-1 at indispensable residues for the binding of gD.<sup>36</sup> Although the expression levels of 3-OS HS also positively correlated with degrees of viral entry and cytotoxicity, its contribution appears to be less than that of nectin-1.

Epigenetic compound library screening indicated that several compounds upregulated nectin-1 expression on nectin-1<sup>-</sup> or nectin-1<sup>low</sup> cell lines and viral entry. However, it did not lead to the induction or enhancement of nectin-1-mediated oncolytic effects (data not shown), possibly because the induction of nectin-1 was weak. More potent epigenetic upregulation of nectin-1 may extend the applicability of oncolytic HSV-1 therapy.

Intratumor injection of T-01 into subcutaneous tumors of GRANTA-519 and ED-40515(+) in the SCID Beige mice was highly effective despite the low levels of T-01

replication in these cell lines in vitro. The apparent discrepancy between the inefficient viral replication in tumor cells in vitro and the strong antitumor effect in immunodeficient mice in vivo is intriguing, although the reason remains to be unknown.

Using an immunocompetent mouse model (E.G7-OVA-nectin-1), we showed that intratumoral injection of T-01 systemically induced antigen (OVA)-specific antitumor CD8<sup>+</sup> T cell responses. Of note, OVA-specific T cells accumulated in both injected and non-injected tumors to the same extent, whereas they scarcely accumulated in the spleen, indicating that the antigen-specific T cells were not diluted in the systemic circulation but were efficiently concentrated at tumor sites.

Various oncolytic viruses have been applied to hematological malignancies via an intravenous route.<sup>9</sup> However, intravenously administered viruses are extensively diluted in the systemic circulation and also rapidly induce the production of neutralizing antiviral antibodies, which hinders repeated injection. Local intratumor injection of HSV-1 induces a systemic immune-mediated effect, which is augmented by combining with immune checkpoint blockade.<sup>37</sup> In addition, oncolytic HSV-1 is not toxic to human hematopoietic cells, as used to purge contaminating solid tumor cells from an autologous bone marrow graft.<sup>12</sup> Thus, HSV-1 may be applicable to tumor-forming hematological malignancies such as lymphoma for intra-tumor injection as well as, if safety is confirmed,

to marrow-located malignancies such as leukemia and myeloma for loco-regional intra-marrow injection, which is easy to perform.

In conclusion, we showed that oncolytic HSV-1 is a viable therapy for hematological malignancies. The expression of nectin-1 rather than defects in the cellular antiviral machineries is a decisive factor to make tumor cells susceptible to HSV-1 and may predict optimal efficacy. Systemic tumor-specific CD8<sup>+</sup> T cell responses efficiently concentrate in tumor sites, suggesting that local intratumor injection of HSV-1 is expected to provoke effective immune responses even for systemic tumors such as hematological malignancies.

## **Materials and Methods**

### **Cell lines and antibodies**

Human cell lines of hematological malignancies are listed in Table S1. Culture conditions of each cell line are described in the Supplemental Methods. E.G7-OVA (ATCC) was derived from the C57BL/6 mouse T-cell lymphoma cell line EL4 by transducing OVA. Antibodies used in this study are listed in Table S3.

### **Viruses**

T-01 and T-GFP (EGFP-expressing T-01) are HSV-1 strain F-based oncolytic viruses containing modification in the same 3 genes as in G47 $\Delta$ .<sup>13</sup> The difference between G47 $\Delta$  and T-01 is that the *ICP6* gene is inactivated by insertion of the *LacZ* gene in the former,<sup>4</sup> whereas the *ICP6* gene is replaced by the CMV promoter, poly(A), and the *LacZ* gene in the latter.<sup>13</sup> Virus stocks were prepared as described with modifications.<sup>38</sup> Briefly, subconfluent monolayers of Vero cells were infected and cultured in VP-SFM (Thermo Fisher, Waltham, MA), and infected cells were harvested when a total cytopathic effect was observed. After a freeze-thaw/sonication regimen, cell debris was removed by low-speed centrifugation, and then virus was concentrated by high-speed centrifugation. The viral pellet was resuspended in Dulbecco's phosphate-buffered saline (DPBS; Sigma-Aldrich, St. Louis, MO) containing 10% glycerol and titrated by plaque assay on Vero cells. Mock extracts were prepared identically, except that DPBS containing 10% glycerol was used in place of virus during the infection step.

### **Flow cytometry analysis**

To analyze the protein expression levels on the cell membrane, samples were analyzed on the Accuri™ C6 Flow Cytometer (BD Biosciences, Franklin Lakes, NJ). Data were analyzed using FlowJo software (BD Biosciences).

### **Cytotoxicity assay in a 3D spheroid culture model**

Cells ( $1 \times 10^5$ ) were seeded in 1.5 mL tubes and pelleted. The cells were infected with virus or “mock” in a volume of 100  $\mu$ L and incubated at 37°C for 1 hour. After adding 900  $\mu$ L of culture medium (total 1 mL), the infected cells were seeded at densities of  $1 \times 10^4$  or  $2 \times 10^4$  cells/well (200  $\mu$ L/well) in PrimeSurface 96U multi-well plates (Sumitomo Bakelite, Tokyo, Japan) and incubated at 37°C for 72 hours. For cell lines, the cells were stained with trypan blue, and the numbers of viable cells were counted with Countess™ II FL Automated Cell Counter (Thermo Fisher). Cell lines were defined as susceptible to T-01, when viability at MOI 1.0 or less decreased significantly compared with mock treatment. For clinical samples, cells were stained with propidium iodide (BioLegend, San Diego, CA) and monoclonal antibodies (mAbs) to gate tumor cells, and were analyzed by flow cytometry. After gating tumor cells, viable cells were detected as propidium iodide-negative cells. Tumor cells from clinical samples were defined as susceptible to T-01, when viability at MOI 10 decreased by 20% or more compared with mock treatment. Acyclovir was purchased from Fujifilm Wako (Osaka, Japan) and dissolved in DMSO.

### **Real-time PCR for the gB gene**

DNA was isolated using a QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). The samples were run on a ViiA7 Real-Time PCR System (Applied Biosystems, Waltham, MA). Amplification was performed using TaqMan Fast Advanced Master Mix (Thermo Fisher) as follows: 95°C for 20 seconds followed by 40 cycles of 95°C for 3 seconds and 60°C for 30 seconds. All the experiments were performed in triplicate. The TaqMan probe sequence for the gB gene was 5'-CACACCTGCGAAACGGTGACGTCTT-3'. Primer sequences used were: forward: 5'- GGCGCGGTCCTCAAAGAT-3', reverse: 5'- AGAACATCGCCCCGTACAAG-3'. DNA from T-01 with a known plaque forming unit (pfu) was used as a control to quantify the amount of gB DNA of samples with pfu.

### **HSV-1 entry assay**

Cells were seeded in 1.5 mL tubes and pelleted. The cells infected with T-GFP or mock were seeded at densities of  $1 \times 10^5$  cells/well in PrimeSurface 96U multi-well plates and incubated at 37°C for 4 hours. The cells were analyzed by flow cytometry to detect entry of T-GFP.

### **ATP and HMGB1 release assay**

After cell death induction, secreted extracellular ATP was measured using a CellTiter-Glo 2.0 Assay (Promega, Madison, WI) in accordance with the manufacturer's protocol. Secreted HMGB1 was detected by western blotting after concentrating proteins in the supernatants using Amicon Ultra Centrifugal Filters (Millipore, Burlington, MA).

### **Clinical samples**

Written informed consent was obtained from all the patients. The study was conducted in accordance with the principles of the Helsinki Declaration and was approved by Ethics Committees of each hospital (Kagawa University Hospital, Sakaide City Hospital, and Kagawa Prefectural Central Hospital).

### **Animal experiments**

Mouse experiments were conducted in accordance with the guidelines approved by the Animal Care and Use Committee of Kagawa University. Cell lines together with Matrigel (BD Biosciences) were implanted subcutaneously into the flank of SCID Beige mice or C57BL/6 mice (Charles River Laboratories Japan, Inc., Yokohama, Japan), and T-01 or mock was injected intratumorally. The tumor size was measured, and OVA-specific CD8<sup>+</sup> T cells in tumors and spleen were detected using H-2K<sup>b</sup> OVA tetramer

(MBL, Nagoya, Japan), as detailed in the Supplemental Methods.

### **Statistical analyses**

Statistical analysis was conducted using a 2-tailed unpaired t-test, non-repeated measures ANOVA followed by Dunnett's test or SNK test, or Spearman's correlation, as described in Figure Legends.  $P < 0.05$  was considered statistically significant.

### **Authorship Contributions**

Conceptualization, N.K.; Methodology, T.T.; Investigation, R.I., Y.K., M.O., and S.U.; Resources, O.I., A.M., T.T., K.K., and T.H.v K.; Writing – Original Draft, R.I. and N.K.; Writing – Reviewing & Editing, T.K., N.S., A.T.-K., and N.K.; Supervision, T.T. and N.K.; Funding Acquisition, T.T. and N.K.

### **Acknowledgements**

We thank Dr. Y. Ino (Teikyo University, Japan) for support and discussion, Dr. H. Arase (Osaka University, Japan) for providing us with mouse anti-human PILR $\alpha$  mAb, Dr. M. Nishikori (Kyoto University, Japan) for providing us with a chemical library for epigenetics research, Dr. M. Nishikori, Dr. K. Shimoda (Miyazaki University, Japan), Dr.

K. Imada (Japanese Red Cross Osaka Hospital, Japan), and Dr. M. Maeda (Institute for Frontier Life and Medical Sciences, Kyoto University, Japan) for providing us with cell lines, and Mr. R. Kojima, Mr. A. Kondo, Ms. K. Fukunaga, and Ms. M. Iwai for excellent technical support. The image of Graphical Abstract is from TogoTV (© 2016 DBCLS TogoTV).

This study was supported by JSPS KAKENHI Grant Numbers JP15K09501 and JP18K08359, AMED under Grant Number JP17ck0106144, and a Grant (2018-1024) from International Joint Usage/Research Center, the Institute of Medical Science, The University of Tokyo. R. Ishino was supported by Iwadare Scholarship Foundation.

#### **Conflict of interest**

The authors declare no competing financial interests.

## References

1. Bommareddy, P.K., Shettigar, M., and Kaufman, H.L. (2018). Integrating oncolytic viruses in combination cancer immunotherapy. *Nat. Rev. Immunol.* *18*, 498-513.
2. Chen, Daniel S., and Mellman, I. (2013). Oncology Meets Immunology: The Cancer-Immunity Cycle. *Immunity* *39*, 1-10.
3. Bommareddy, P.K., Peters, C., Saha, D., Rabkin, S.D., and Kaufman, H.L. (2018). Oncolytic Herpes Simplex Viruses as a Paradigm for the Treatment of Cancer. *Annu. Rev. Cancer Biol.* *2*, 155-173.
4. Mineta, T., Rabkin, S.D., Yazaki, T., Hunter, W.D., and Martuza, R.L. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. *Nat. Med.* *1*, 938-943.
5. Todo, T., Martuza, R.L., Rabkin, S.D., and Johnson, P.A. (2001). Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. *Proc. Natl. Acad. Sci. U. S. A.* *98*, 6396-6401.
6. Bierman, H.R., Crile, D.M., Dod, K.S., Kelly, K.H., Petrakis, N.L., White, L.P., et al. (1953). Remissions in leukemia of childhood following acute infectious disease: staphylococcus and streptococcus, varicella, and feline panleukopenia. *Cancer* *6*, 591-605.
7. Bluming, A.Z., and Ziegler, J.L. (1971). Regression of Burkitt's lymphoma in association with measles infection. *Lancet* *2*, 105-106.
8. Taqi, A.M., Abdurrahman, M.B., Yakubu, A.M., and Fleming, A.F. (1981). Regression of Hodgkin's disease after measles. *Lancet* *1*, 1112.
9. Bais, S., Bartee, E., Rahman, M.M., McFadden, G., and Cogle, C.R. (2012). Oncolytic virotherapy for hematological malignancies. *Adv. Virol.* *2012*, 186512.
10. Tazzyman, S., Muthana, M., Harrison, J., Lewis, C., Conner, J., and Chantry, A. (2015). Development of a Trojan horse oncolytic virus for treatment of myeloma. *J. Clin. Oncol.* *33*, e14035-e14035.
11. Ghose, J., Russell, L., Caserta, E., Santhanam, R., Jaime-Ramirez, A.C., Viola, D., et al. (2016). Exploring the Possibility of Using Herpes Simplex Virus in Oncolytic Virotherapy of Multiple Myeloma. *Blood* *128*, 4467-4467.
12. Wu, A., Mazumder, A., Martuza, R.L., Liu, X., Thein, M., Meehan, K.R., et al. (2001). Biological Purging of Breast Cancer Cells Using an Attenuated Replication-competent Herpes Simplex Virus in Human Hematopoietic Stem Cell Transplantation. *Cancer Res.* *61*, 3009-3015.
13. Fukuhara, H., Ino, Y., Kuroda, T., Martuza, R.L., and Todo, T. (2005). Triple Gene-Deleted Oncolytic Herpes Simplex Virus Vector Double-Armed with Interleukin 18 and Soluble B7-1 Constructed by Bacterial Artificial Chromosome-Mediated System. *Cancer Res.* *65*, 10663-10668.
14. Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., et al. (2014).

- Consensus guidelines for the detection of immunogenic cell death. *Oncoimmunology* 3, e955691.
15. Geraghty, R.J., Krummenacher, C., Cohen, G.H., Eisenberg, R.J., and Spear, P.G. (1998). Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. *Science* 280, 1618-1620.
  16. Montgomery, R.I., Warner, M.S., Lum, B.J., and Spear, P.G. (1996). Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. *Cell* 87, 427-436.
  17. Shukla, D., Liu, J., Blaiklock, P., Shworak, N.W., Bai, X., Esko, J.D., et al. (1999). A Novel Role for 3-O-Sulfated Heparan Sulfate in Herpes Simplex Virus 1 Entry. *Cell* 99, 13-22.
  18. Satoh, T., Arii, J., Suenaga, T., Wang, J., Kogure, A., Uehori, J., et al. (2008). PILRALpha is a herpes simplex virus-1 entry coreceptor that associates with glycoprotein B. *Cell* 132, 935-944.
  19. Arii, J., Goto, H., Suenaga, T., Oyama, M., Kozuka-Hata, H., Imai, T., et al. (2010). Non-muscle myosin IIA is a functional entry receptor for herpes simplex virus-1. *Nature* 467, 859-862.
  20. Arii, J., Hirohata, Y., Kato, A., and Kawaguchi, Y. (2015). Nonmuscle myosin heavy chain IIb mediates herpes simplex virus 1 entry. *J Virol* 89, 1879-1888.
  21. Xia, T., Konno, H., Ahn, J., and Barber, Glen N. (2016). Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis. *Cell Rep.* 14, 282-297.
  22. Xia, T., Konno, H., and Barber, G.N. (2016). Recurrent Loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis. *Cancer Res.* 76, 6747-6759.
  23. de Queiroz, N.M.G.P., Xia, T., Konno, H., and Barber, G.N. (2019). Ovarian Cancer Cells Commonly Exhibit Defective STING Signaling Which Affects Sensitivity to Viral Oncolysis. *Mol. Cancer Res.* 17, 974-986.
  24. Unterholzner, L., Keating, S.E., Baran, M., Horan, K.A., Jensen, S.B., Sharma, S., et al. (2010). IFI16 is an innate immune sensor for intracellular DNA. *Nat. Immunol.* 11, 997-1004.
  25. Ishikawa, H., and Barber, G.N. (2008). STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. *Nature* 455, 674-678.
  26. Gale, M., and Katze, M.G. (1998). Molecular Mechanisms of Interferon Resistance Mediated by Viral-Directed Inhibition of PKR, the Interferon-Induced Protein Kinase. *Pharmacol. Ther.* 78, 29-46.
  27. He, B., Gross, M., and Roizman, B. (1997). The  $\gamma$ 134.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1 $\alpha$  to dephosphorylate the  $\alpha$  subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. *Proc. Natl. Acad. Sci. U. S. A.* 94, 843-848.
  28. Farassati, F., Yang, A.D., and Lee, P.W. (2001). Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. *Nat Cell Biol* 3, 745-750.
  29. Cassady, K.A., Gross, M., and Roizman, B. (1998). The second-site mutation in the herpes simplex

- virus recombinants lacking the gamma134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha. *J. Virol.* 72, 7005-7011.
30. Samudio, I., Rezvani, K., Shaim, H., Hofs, E., Ngom, M., Bu, L., et al. (2016). UV-inactivated HSV-1 potently activates NK cell killing of leukemic cells. *Blood* 127, 2575-2586.
  31. Huang, Y.-Y., Yu, Z., Lin, S.-F., Li, S., Fong, Y., and Wong, R.J. (2007). Nectin-1 Is a Marker of Thyroid Cancer Sensitivity to Herpes Oncolytic Therapy. *J. Clin. Endocrinol. Metab.* 92, 1965-1970.
  32. Yu, Z., Adusumilli, P.S., Eisenberg, D.P., Darr, E., Ghossein, R.A., Li, S., et al. (2007). Nectin-1 Expression by Squamous Cell Carcinoma is a Predictor of Herpes Oncolytic Sensitivity. *Mol. Ther.* 15, 103-113.
  33. Wang, P.Y., Currier, M.A., Hansford, L., Kaplan, D., Chiocca, E.A., Uchida, H., et al. (2013). Expression of HSV-1 receptors in EBV-associated lymphoproliferative disease determines susceptibility to oncolytic HSV. *Gene Ther.* 20, 761-769.
  34. Jackson, J.D., McMorris, A.M., Roth, J.C., Coleman, J.M., Whitley, R.J., Gillespie, G.Y., et al. (2014). Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines. *Gene Ther.* 21, 984-990.
  35. Wang, P.Y., Swain, H.M., Kunkler, A.L., Chen, C.Y., Hutzen, B.J., Arnold, M.A., et al. (2016). Neuroblastomas vary widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibility. *Gene Ther.* 23, 135-143.
  36. Di Giovine, P., Settembre, E.C., Bhargava, A.K., Luftig, M.A., Lou, H., Cohen, G.H., et al. (2011). Structure of Herpes Simplex Virus Glycoprotein D Bound to the Human Receptor Nectin-1. *PLoS Pathog.* 7, e1002277.
  37. Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R.H.I., Michielin, O., et al. (2017). Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. *Cell* 170, 1109-1119.
  38. Todo, T., Feigenbaum, F., Rabkin, S.D., Lakeman, F., Newsome, J.T., Johnson, P.A., et al. (2000). Viral Shedding and Biodistribution of G207, a Multimutated, Conditionally Replicating Herpes Simplex Virus Type 1, after Intracerebral Inoculation in Aotus. *Mol. Ther.* 2, 588-595.

## Figure legends

### **Figure 1. T-01 induces immunogenic cell death of human hematological tumor cell lines.**

(A, B) Jurkat, GRANTA-519, and Ramos cells were treated with mock or T- 01 (MOI 0.01, 0.1, and 1.0) (A). Jurkat cells were treated with mock, intact T-01 or UV-inactivated T- 01 (MOI 0.1, 1.0, and 10) (B). After 3 days, the number of viable cells was counted. The data are shown as the mean  $\pm$  SE of 3 independent experiments. Statistical analysis was conducted using non-repeated measures ANOVA followed by Dunnett's test.  $**P < 0.01$ . (C, D) Jurkat and GRANTA-519 cells were treated with mock or the indicated MOI of T-01. After 24 hours, (C) ATP in the supernatants was measured using a CellTiter-Glo 2.0 Assay. The data are shown as the mean  $\pm$  SE of 3 independent experiments. Statistical analysis was conducted using a 2-tailed unpaired t-test.  $*P < 0.05$ ,  $**P < 0.01$ . (D) HMGB1 in the supernatants was detected using western blotting. The data are representative of 3 independent experiments. See also Figure S1.

### **Figure 2. A low level of replication of T-01 in hematological tumor cells.**

(A) Vero cells were treated with T-01 (MOI 0.1) for 24 hours in the presence of DMSO

or 10  $\mu$ M acyclovir. Jurkat, GRANTA-519, ED-40515(+), MT-2, and RPMI 8226 cells were treated with T-01 (MOI 1.0) for the indicated periods. The amounts of the gB gene of HSV-1 were measured by real-time PCR, and were expressed as the ratios to the amounts at the time of culture start. The data are shown as the mean  $\pm$  SE of 2 (Vero cells) or 3 (the other cells) independent experiments. (B) Jurkat and GRANTA-519 cells were treated with T-01 (MOI 1.0) for the indicated periods in the presence of DMSO (control) or 10  $\mu$ M acyclovir. The amounts of the gB gene were measured and expressed as in (A). The data are shown as the mean  $\pm$  SE of 3 independent experiments. (C) Jurkat and GRANTA-519 cells were treated with mock or T- 01 (MOI 0.01, 0.1, and 1.0) in the presence of DMSO (control) or 10  $\mu$ M acyclovir. After 3 days, the number of viable cells was counted. The data are shown as the mean  $\pm$  SE of 3 independent experiments. Statistical analysis was conducted using non-repeated measures ANOVA followed by SNK test. \* $P < 0.05$ , \*\* $P < 0.01$ .

**Figure 3. The expression levels of nectin-1 and 3-OS HS on the cell lines correlate with viral entry and cytotoxicity.**

(A) Viral entry versus cytotoxicity, (B) nectin-1 expression, (C) HVEM expression, and (D) 3-OS HS expression versus viral entry and cytotoxicity. Viral entry is indicated as

percentages of T-GFP-positive cells at MOI 1.0 after 4-hour culture. Cytotoxicity was calculated as  $1 - (\text{viable cell number with T-01} / \text{viable cell number with mock}) \times 100 (\%)$  after treatment with T-01 (MOI 1.0) for 3 days. The expression of nectin-1, HVEM, and 3-OS HS is indicated as the mean fluorescence intensity (MFI) ratios compared with cells stained with isotype-matched control mAbs (nectin-1 and HVEM) or those stained by omitting anti-heparan sulfate antibody HS4C3 (3-OS HS). Each dot indicates each cell line. Asterisks in (B) indicate HL-60. Statistical analysis was conducted using Spearman's correlation. See also Figures S2-4.

**Figure 4. The expression levels of nectin-1 on clinical samples correlate with entry and cytotoxicity by T-01.**

(A) nectin-1 expression and (B) HVEM expression versus cytotoxicity. Nectin-1 and HVEM expression is indicated as the MFI ratio compared with cells stained with isotype-matched control mAbs. Cytotoxicity was calculated as  $1 - (\text{viable cell percentage with T-01} / \text{viable cell percentage with mock}) \times 100 (\%)$  after treatment with T-01 (MOI 10) for 3 days. Each dot indicates each cell line. Red and black dots indicate samples from relapsed and untreated patients, respectively. Statistical analysis was conducted using Spearman's correlation. See also Figure S6.

**Figure 5. Nectin-1 knockdown and transfection affect viral entry and cytotoxicity.**

(A) Nectin-1 expression (upper panels) and viral entry (lower panels) in Jurkat and THP-1 cells after knockdown of nectin-1 with shRNA. Nectin-1 expression is shown as the MFI ratio compared with cells stained with isotype-matched control mAbs. Viral entry is indicated as percentages of T-GFP-positive cells at MOI 1.0. 62933 indicates cells with nectin-1 knockdown. The data are shown as the mean  $\pm$  SE of 3 independent measurements. Statistical analysis was conducted using a 2-tailed unpaired t-test.  $*P < 0.05$ ,  $**P < 0.01$ . (B) Nectin-1 expression (left panels), viral entry (middle panels), and cytotoxic effects of T-01 (right panels) on Ramos (upper panels) and E.G7-ONA (lower panels) transfected with human nectin-1. The data are shown as the mean  $\pm$  SE of 3 independent measurements. Statistical analysis was conducted using non-repeated measures ANOVA followed by Dunnett's test.  $*P < 0.05$ ,  $**P < 0.01$ .

**Figure 6. Antitumor effects of T-01 in vivo in immunodeficient mice.**

(A) Treatment schema. GRANTA-519 or ED-40515(+) cells were subcutaneously implanted into the left flank of SCID Beige mice. Mock or T-01 ( $0.2 \times 10^6$  or  $1.0 \times 10^6$  pfu) was injected into the established tumor on day 0 and 3. The tumor size was measured

every 2 or 3 days. (B) Tumor growth curves ( $n = 7$  and  $8$  for GRANTA-519 and ED-40515(+), respectively). Arrows indicate injection of mock or T-01. The data are shown as the mean  $\pm$  SE. Statistical analysis was conducted using non-repeated measures ANOVA followed by Dunnett's test.  $**P < 0.01$ .

**Figure 7. Antitumor effects of T-01 in vivo in immunocompetent mice.**

(A) Treatment schema. E.G7-OVA-nectin-1 was subcutaneously implanted into the right and left flanks of C57BL/6 mice. Mock or T-01 ( $2.0 \times 10^6$  pfu) was injected into the established right tumor on day 0 and 3. The tumor size was measured every 2 or 3 days.

(B) Tumor growth curves ( $n = 8$ ). Arrows indicate injection of mock or T-01. The data are shown as the mean  $\pm$  SE. Statistical analysis was conducted using a 2-tailed unpaired t-test.  $*P < 0.05$ .

(C) Tetramer staining of tumor-infiltrating lymphocytes (TILs) and spleen cells. TILs from the T-01-injected right-side tumor, those from the T-01-non-injected left-side tumor, and spleen cells were isolated 10 days after the second injection of mock or T-01. The frequency (%) of H-2K<sup>b</sup> OVA tetramer-positive cells among CD8<sup>+</sup> T cells was measured by flow cytometry. The statistical differences of the tetramer-positive cells between mock- or T-01-treated mice were analyzed ( $n = 4$ ) (upper panels). The data are shown as the mean  $\pm$  SE. Statistical analysis was conducted using a 2-tailed

unpaired t-test. \*\*\* $P < 0.001$ . Lower panels show representative data of TILs stained with the OVA tetramer.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5





Figure 6

A



B








Figure 7



## Figure S1

MyeloidT cellB cell

**Figure S1 related to Figure 1. T-01 kills human cell lines derived from various lineages of hematological malignancies.**

Human hematological tumor cell lines of myeloid, T cell, and B cell lineages were treated with mock or T-01 (MOI 0.01, 0.1, and 1.0). After 3 days, the number of viable cells was counted. The data are shown as the mean  $\pm$  SE of 3 independent experiments. Statistical analysis was conducted using non-repeated measures ANOVA followed by Dunnett's test.

\* $P < 0.05$ , \*\* $P < 0.01$ .

Figure S2






Figure S2C




**Figure S2 related to Figure 3. The degrees of viral entry are highly variable among the cell lines.**

(A) Cell lines were treated with T-GFP (MOI 1.0) for 4 hours. The degrees of viral entry are shown by flow cytometry with forward scatter versus EGFP. The left and right panels of each cell line indicate cells without and with T-GFP, respectively. The percentages of EGFP-positive and negative cells are indicated on the plot. The cell lines susceptible to T-01 are labeled with red.

(B) A graph showing the percentages of cells with viral entry as detected by EGFP positivity shown in (A). The data are shown as the mean  $\pm$  SE of 3 independent experiments.

(C) Graphs showing the percentages of cells with viral entry as detected by EGFP positivity at 4 and 24 hours. The cell lines with low levels of viral entry at 4 hours are shown. (i) T-01-susceptible cell lines, (ii) T-01-resistant cell lines. The data are shown as the mean  $\pm$  SE of 3 independent experiments.

Figure S3




**Figure S3 related to Figure 3. Expression of nectin-1, HVEM, 3-OS HS, and PILR $\alpha$  on lymphocytes and monocytes in human peripheral blood.**

Lymphocytes and monocytes were gated based on forward and side scatters. Red histograms represent cells stained with isotype-matched control mAbs. Anti-heparan sulfate antibody HS4C3 was omitted for the negative control of 3-OS HS. The data are representative of 3 independent experiments.


Figure S4A Nectin-1 expression

Myeloid


THP-1




SET-2




SKM-1




MEG-01




HEL



HL-60




CHRF-288-11




T cell


Jurkat




ATL-43T




SYK-11L(+)




ED-40515(+)




MT-2




HuT 102



SU-DHL-1




SR-786




B cell


GRANTA-519




RPMI 8226




KMS-12-BM




MM.1S




Raji




KM-H2




NCI-H929




U266



FL-318



Ramos



KLS-1




Figure S4 related to Figure 3. Expression of nectin-1 (A), HVEM (B), and 3-OS HS (C) on the cell lines.


(A) Red histograms represent cells stained with isotype-matched control mAbs. The cell lines susceptible to T-01 are labeled with red. The data are representative of 3 independent experiments.

Figure S4B


HVEM expression

Myeloid


THP-1




SET-2




SKM-1




MEG-01




HEL



HL-60




CHRF-288-11




T cell


Jurkat




ATL-43T




SYK-11L(+)




ED-40515(+)




MT-2




HuT 102



SU-DHL-1




SR-786




B cell


GRANTA-519




RPMI 8226




KMS-12-BM




MM.1S




Raji




KM-H2




NCI-H929




U266



FL-318



Ramos



KIS-1





Figure S4 related to Figure 3. Expression of nectin-1 (A), HVEM (B), and 3-OS HS (C) on the cell lines.

(B) Red histograms represent cells stained with isotype-matched control mAbs. The cell lines susceptible to T-01 are labeled with red. The data are representative of 3 independent experiments.


Figure S4C 3-OS HS expression

Myeloid


THP-1




SET-2




SKM-1




MEG-01




HEL



HL-60




CHRF-288-11




T cell


Jurkat




ATL-43T




SYK-11L(+)




ED-40515(+)




MT-2




Hut 102



SU-DHL-1




SR-786




B cell


GRANTA-519




RPMI 8226




KMS-12-BM




MM.1S




Raji




KM-H2




NCI-H929




U266



FL-318



Ramos



KIS-1





Figure S4 related to Figure 3. Expression of nectin-1 (A), HVEM (B), and 3-OS HS (C) on the cell lines.

(C) Red histograms represent cells stained by omitting anti-heparan sulfate antibody HS4C3. The cell lines susceptible to T-01 are labeled with red. The data are representative of 3 independent experiments.

Figure S5



**Figure S5. Expression of NMHC-IIA and IIB in the cell lines.**

(A) NMHC-IIA (NM-IIA), (B) NMHC-IIB (NM-IIB), and  $\beta$ -actin in cell extracts were detected by western blotting. The cell lines susceptible to T-01 are labeled with red. The data are representative of 3 independent experiments.

Figure S6





Figure S6 related to Figure 4. Susceptibility to T-01 and expression of nectin-1 and HVEM on clinical samples.

Mononuclear cells from clinical samples were stained with appropriate combinations of mAbs, based on prior flow cytometric analysis of each clinical sample. Tumor cells within each sample were gated before analysis. Left: dot plots of forward scatter and propidium iodide with gating of viable cells after treatment with mock or T-01 at the indicated MOI for 3 days. Percentages of viable cells are indicated on each plot. The samples regarded as susceptible to T-01 are labeled with red. Middle: viability after treatment with mock or T-01 (MOI 0.1, 1, or 10) for 3 days, calculated as (viable cell percentage with T-01/viable cell percentage with mock) x 100 (%). Right: expression of nectin-1 and HVEM on tumor cells. Red histograms represent cells stained with isotype-matched control mAbs.

Figure S7




**Figure S7. Nectin-1 expression and viral entry are upregulated by epigenetic regulation.**


(A) Ramos and HEL cells were treated with reagents contained in a chemical library for epigenetics research at 1  $\mu$ M for 24 hours. Nectin-1 expression and cell viability are shown by columns and circles, respectively (in red for the cells treated with the indicated reagents). Nectin-1 expression was detected by flow cytometry. Cell viability was detected as trypan blue exclusion. (B) Ramos, HEL, THP-1, and SYK-11L(+) cells were treated with decitabine, I-BET726, or LMK-235 at the indicated concentrations for 24 hours. Nectin-1 expression was detected by flow cytometry. The data are shown as the mean  $\pm$  SE of 3 independent measurements. (C) Cells were treated with the indicated reagents for 24 hours. Thereafter, the cells were cultured with T-GFP for 4 hours. Viral entry was detected using flow cytometry. The data are shown as the mean  $\pm$  SE of 3 independent measurements. Statistical significance was examined against DMSO-treated control cells. Statistical analysis was conducted using non-repeated measures ANOVA followed by Dunnett's test. \* $P$  < 0.05, \*\* $P$  < 0.01.

Figure S8

A




B



**Figure S8. Expression and activity of the cGAS-STING pathway.**

(A) cGAS, STING, and  $\beta$ -actin in cell extracts were detected by western blotting. The cell lines susceptible to T-01 are labeled with red. (B) Phosphorylated TBK1 (p-TBK1), total TBK1, p-IRF3, and total IRF3 in THP-1, ATL-43T, and MT-2 in cell extracts were detected by western blotting after stimulation with mock or T-01 (MOI 10) for 10 hours (in the left panels) or with DMSO or HSV-60 (10  $\mu$ g/mL) for 3 hours (in the right panels). The cell lines susceptible to T-01 are labeled with red. The data are representative of 3 independent experiments.

Figure S9




**Figure S9. Correlation between IFN-β mRNA expression and cytotoxicity by T-01.**


The 14 cell lines examined in Figure S8A were infected with T-01 at MOI 1.0 for 24 hours. The expression levels of IFN-β mRNA was measured by quantitative RT-PCR. Cytotoxicity was calculated as  $1 - (\text{viable cell number with T-01} / \text{viable cell number with mock}) \times 100$  (%) after treatment with T-01 (MOI 1.0) for 3 days. Statistical analysis was conducted using Spearman' s correlation.

Figure S10

A



B



**Table S1 related to Figure 1. Human cell lines of hematological malignancies**

| Cell line       | Origin                          | Source       | Cytotoxicity |
|-----------------|---------------------------------|--------------|--------------|
| Myeloid-derived |                                 |              |              |
| THP-1           | Acute monocytic leukemia        | JCRB         | +            |
| SET-2           | Acute megakaryoblastic leukemia | K.Shimoda    | +            |
| SKM-1           | Acute myeloid leukemia          | JCRB         | +            |
| MEG-01          | Chronic myeloid leukemia        | ATCC         | +            |
| HEL             | Acute erythroid leukemia        | JCRB         | -            |
| HL-60           | Acute promyelocytic leukemia    | ATCC         | -            |
| CHRF-288-11     | Acute megakaryoblastic leukemia | K. Shimoda   | -            |
| T cell-derived  |                                 |              |              |
| Jurkat          | Acute T-cell leukemia           | K. Imada     | +            |
| ATL-43T         | Adult T-cell leukemia           | M. Maeda     | +            |
| SYK-11L(+)      | Adult T-cell leukemia           | K. Imada     | +            |
| ED-40515(+)     | Adult T-cell leukemia           | M. Maeda     | +            |
| MT-2            | Adult T-cell leukemia           | K. Imada     | +            |
| HuT 102         | Adult T-cell leukemia           | M. Nishikori | +            |
| SU-DHL-1        | Anaplastic large cell lymphoma  | M. Nishikori | -            |
| SR-786          | Anaplastic large cell lymphoma  | M. Nishikori | -            |
| B cell-derived  |                                 |              |              |
| GRANTA-519      | Mantle cell lymphoma            | M. Nishikori | +            |
| Raji            | Burkitt lymphoma                | M. Nishikori | +            |
| KM-H2           | Hodgkin lymphoma                | M. Nishikori | +            |
| RPMI 8226       | Plasma cell myeloma             | JCRB         | +            |
| KMS-12-BM       | Plasma cell myeloma             | JCRB         | +            |
| MM.1S           | Plasma cell myeloma             | ATCC         | +            |
| NCI-H929        | Plasmacytoma                    | ATCC         | +            |
| U266            | Plasmacytoma                    | ATCC         | +            |
| Ramos           | Burkitt lymphoma                | M. Nishikori | -            |
| FL-318          | Diffuse large B-cell lymphoma   | M. Nishikori | -            |
| KIS-1           | Diffuse large B-cell lymphoma   | M. Nishikori | -            |

ATCC: American Type Culture Collection

JCRB: Japanese Collection of Research Bioresources Cell Bank

Cytotoxicity : with (+) or without (-) statistically significant cytotoxicity with MOI 0.01, 0.1, or 1.0 of T-01, as shown in Figure S1

**Table S2 related to Figure 4. Clinical samples**

| Patient # | Disease      | Age | Sex | Sample  | Cytotoxicity | Nectin-1 | HVEM |
|-----------|--------------|-----|-----|---------|--------------|----------|------|
| Relapsed  |              |     |     |         |              |          |      |
| 1         | AML          | 62  | M   | PB      | +            | +        | -    |
| 2         | AML          | 68  | F   | PB      | +            | +        | +    |
| 3         | AML          | 78  | F   | PB      | +            | +        | -    |
| 4         | AML          | 85  | M   | PB      | +            | +        | -    |
| 5         | T-LBL        | 31  | M   | PB      | +            | +        | +    |
| 6         | PTCL         | 77  | M   | Ascites | +            | +        | +    |
| 7         | MM           | 68  | F   | Ascites | +            | +        | +    |
| 8         | Plasmacytoma | 69  | M   | PE      | +            | +        | -    |
| 9         | SMZL         | 52  | M   | Spleen  | -            | -        | +    |
| 10        | FL           | 56  | F   | LN      | -            | -        | +    |
| Untreated |              |     |     |         |              |          |      |
| 11        | AML          | 67  | F   | BM      | -            | -        | +    |
| 12        | AML          | 83  | M   | BM      | -            | -        | -    |
| 13        | AML          | 89  | M   | BM      | -            | -        | -    |
| 14        | ATLL         | 65  | F   | PB      | -            | -        | -    |
| 15        | PTCL         | 76  | F   | PE      | -            | -        | +    |

AML: acute myeloid leukemia; T-LBL: T-lymphoblastic leukemia; PTCL: peripheral T-cell lymphoma; MM: multiple myeloma; SMZL: splenic marginal zone lymphoma; FL: follicular lymphoma; PB: peripheral blood; PE: pleural effusion; LN: lymph node

Cytotoxicity positive (+): decrease in viability at MOI 10  $\geq$  20% compared to mock treatment;  
 (-): < 20% compared to mock treatment

Nectin-1, HVEM positive (+): MFI ratio  $\geq$  1.5; negative (-): MFI ratio < 1.5

**Table S3. List of antibodies**

| Reagent                                        | Isotype        | Clone    | Source          | Catalog# |
|------------------------------------------------|----------------|----------|-----------------|----------|
| FITC Mouse IgG1 Isotype                        | Mouse IgG1, k  | MOPC-21  | BD Biosciences  | 555748   |
| FITC anti-human CD38                           | Mouse IgG1, k  | HB7      | BD Biosciences  | 340927   |
| FITC HLA-DR                                    | Mouse IgG2b, k | B8.12.2  | Beckman Coulter | IM0463U  |
| FITC Mouse IgG1 Isotype                        | Mouse IgG1, k  | MOPC-21  | BioLegend       | 400110   |
| FITC Mouse IgG2a Isotype                       | Mouse IgG2a, k | MOPC-173 | BioLegend       | 400208   |
| FITC Mouse IgG2b, k Isotype Ctrl               | Mouse IgG2b, k | MPC-11   | BioLegend       | 400309   |
| FITC anti-human CD117(c-kit)                   | Mouse IgG1, k  | 104D2    | BioLegend       | 313231   |
| FITC anti-human CD19                           | Mouse IgG1, k  | H1B19    | BioLegend       | 302206   |
| FITC anti-human CD138                          | Mouse IgG1, k  | MI15     | BioLegend       | 356508   |
| FITC anti-human CD3                            | Mouse IgG2a, k | HIT3a    | BioLegend       | 300305   |
| FITC anti-human CD14                           | Mouse IgG2a, k | M5E2     | BioLegend       | 301803   |
| FITC anti-human CD34                           | Mouse IgG2a, k | 561      | BioLegend       | 343603   |
| FITC anti-human CD45RO                         | Mouse IgG2a, k | UCHL1    | BioLegend       | 304242   |
| FITC anti-human CD4                            | Mouse IgG2b, k | OKT4     | BioLegend       | 317408   |
| Goat anti-mouse IgG(H&L),FITC conjugate        | Goat IgG       |          | Thermo Fisher   | A24525   |
| PE Mouse IgG1 Isotype                          | Mouse IgG1, k  | 679.1Mc7 | Beckman Coulter | A07796   |
| PE anti-human CD117                            | Mouse IgG1, k  | 104D2D1  | Beckman Coulter | IM2732   |
| PE Mouse IgG1, k Isotype Ctrl(FC)              | Mouse IgG1, k  | MOPC-21  | BioLegend       | 400113   |
| PE anti-human CD111(Nectin-1)                  | Mouse IgG1, k  | R1.302   | BioLegend       | 340404   |
| PE anti-human CD270(HVEM, TR2)                 | Mouse IgG1, k  | 122      | BioLegend       | 318805   |
| PE anti-human CD3                              | Mouse IgG2a, k | HIT3a    | BioLegend       | 300307   |
| APC Mouse IgG1, k Isotype Ctrl(FC)             | Mouse IgG1, k  | X40      | BD Biosciences  | 340442   |
| APC anti-human CD34                            | Mouse IgG1, k  | 581      | BD Biosciences  | 555824   |
| APC anti-human CD38                            | Mouse IgG1, k  | HB7      | BD Biosciences  | 340439   |
| APC Mouse IgG1, k Isotype Ctrl(FC)             | Mouse IgG1, k  | MOPC-21  | BioLegend       | 400122   |
| APC anti-human CD19                            | Mouse IgG1, k  | H1B19    | BioLegend       | 302212   |
| APC Mouse IgG2a, k Isotype Ctrl                | Mouse IgG2a, k | MOPC-173 | BioLegend       | 400219   |
| APC anti-human CD3                             | Mouse IgG2a, k | HIT3a    | BioLegend       | 300311   |
| APC anti-human CD34                            | Mouse IgG2a, k | 561      | BioLegend       | 343608   |
| Alexa Fluor 488 Mouse IgG1, k Isotype Ctrl(FC) | Mouse IgG1,k   | MOPC-21  | BioLegend       | 400132   |
| Alexa Fluor 488 anti-human CD80                | Mouse IgG1,k   | 2D10     | BioLegend       | 305213   |
| Alexa Fluor 488 Mouse IgG2b, k Isotype Ctrl    | Mouse IgG2b,k  | MPC-11   | BioLegend       | 400329   |
| Alexa Fluor 488 anti-human CD86                | Mouse IgG2b,k  | IT2.2    | BioLegend       | 305413   |
| Myosin IIa Antibody                            | Rabbit IgG     |          | Cell Signaling  | 3403     |
| Myosin IIb XP Rabbit mAb                       | Rabbit IgG     | D8H8     | Cell Signaling  | 8824     |
| Myosin IIc Rabibit mAb                         | Rabbit IgG     | D4A7     | Cell Signaling  | 8189     |
| cGAS Rabbit mAb                                | Rabbit IgG     | D1D3G    | Cell Signaling  | 15102    |
| STING Rabbit mAb                               | Rabbit IgG     | D2P2F    | Cell Signaling  | 13647    |
| PKR                                            | Mouse IgG2b, k | B-10     | Santa Cruz      | sc-6282  |
| Anti-PKR(phospho T446)antibody                 | Rabbit IgG     | E120     | Abcam           | ab32036  |
| Anti-PKR(phospho T451)antibody                 | Rabbit IgG     | EPR2152Y | Abcam           | ab81303  |
| Phospho-eIF2a(Ser51) XP Rabbit mAb             | Rabbit IgG     | D9G8     | Cell Signaling  | 3398     |
| TBK1/NAK Rabbit mAb                            | Rabbit IgG     | D1B4     | Cell Signaling  | 3504     |
| Phospho-TBK1/NAK(Ser172)XP Rabbit mAb          | Rabbit IgG     | D52C2    | Cell Signaling  | 5483     |
| IRF-3(D614C)XP Rabbit mAb                      | Rabbit IgG     | D6I4C    | Cell Signaling  | 11904    |
| Phospho-IRF-3(Ser386)XP Rabbit mAb             | Rabbit IgG     | E7J8G    | Cell Signaling  | 37829    |
| Human HMGB1/HMG-1 antibody                     | Mouse IgG2b    | 115603   | R&D systems     | MAB1690  |
| Anti-rabbit IgG,HRP-linked Antibody            | Goat           |          | Cell Signaling  | 7074     |
| Anti-Mouse IgG–Peroxidase antibody             | Rabbit         |          | Sigma-Aldrich   | A9044    |
| Anti-VSV-G tag mAb                             | Mouse          | P5D4     | Abcam           | ab50549  |

## **Supplemental Methods**

### **Cell lines**

Cells except for the following cell lines were cultured in RPMI-1640 (Sigma-Aldrich) containing 10% heat-inactivated fetal bovine serum (FBS) (Corning, Corning, NY) and 5 mM HEPES (Nacalai Tesque, Kyoto, Japan). SET-2 cells were cultured in DMEM (Sigma-Aldrich) containing 10% FBS, 10  $\mu$ M 2-mercaptoethanol (Fujifilm Wako), and MEM non-essential amino acid solution (Fujifilm Wako). CHRF-288-11 and HL-60 cells were cultured in IMDM (Fujifilm Wako) containing 10% and 20% FBS, respectively. ED-40515(+), ATL-43T, and SYK-11L(+) cells were cultured in RPMI-1640 containing 10% FBS, 5mM HEPES, and 8 U/mL human IL-2 (BioLegend). Vero and HEK293T cells were cultured in DMEM containing 10% FBS.

### **Plasmids and transfection**

Human nectin-1 shRNA (#245117), control shRNA (#246995), human nectin-1 expression (#281558), and pLX304 control (#25890) lentiviral vector plasmids were purchased from Dharmacon (Lafayette, CO). QIAprep Spin Miniprep Kit (Qiagen) was used for purification of the plasmid. Approximately 24 hours before transfection, HEK293T cells ( $5 \times 10^5$ ) were seeded into 6-well culture plates in 2 mL growth medium (DMEM + 10% FBS) and incubated at 37 °C, 5% CO<sub>2</sub> overnight. When cells were about 85–95% confluent, half of the medium was replaced. Transfection of DNA mixture of packing plasmids and lentivirus vectors was performed by using Lipofectamine 3000 (Thermo Fisher) according to the manufacturer's instructions. About 16-20 hours after transfection, the transfection medium was replaced with 2 mL fresh complete growth medium (high glucose DMEM + 10% FBS) and cells were incubated at 37 °C for additional 48 hours. Thereafter, lentiviral supernatants were harvested and centrifuged at 1600g, 4 °C for 10 min. The supernatant was stored in -80°C until used. Cell lines (Jurkat, THP-1, Ramos, and E.G7-OVA) were infected by adding half the volume with the lentiviral supernatants plus polybrene (Nacalai Tesque) at a 5  $\mu$ g/mL final concentration. The infected cells were incubated for 24 hours and then given fresh growth media for 24–48 hours before beginning selection. The infected cells were propagated in medium containing 10  $\mu$ g/mL puromycin (InvivoGen, San Diego, CA) or 10  $\mu$ g/mL blasticidin S (Fujifilm Wako).

### **Detection of 3-OS HS**

After blocking with 5% human IgG and 1% goat serum for 15 min on ice, cells were stained with a vesicular stomatitis virus (VSV)-tagged single chain variable fragment antibody (HS4C3) that recognizes 3-*O*-sulfated oligosaccharide structures<sup>1</sup> for 30 min on ice. After washing, cells were stained with mouse anti-VSV-G tag mAb (Abcam, Cambridge, UK) for 30 min on ice, followed by staining with FITC-conjugated goat anti-mouse IgG (H+L) (Thermo Fisher) for 30 min on ice. Negative control cells were stained by omitting HS4C3. Cells were analyzed by flow cytometry.

### **Western blotting**

Equal numbers of cells were resolved on SDS-PAGE (Criterion™ TGX™). Trans-Blot Turbo™ Transfer System was used for the transfer of proteins to PVDF membranes (all reagents from Bio-Rad, Hercules, CA). The membrane was blocked in 5% Difco™ skim milk (BD Biosciences) or 5% bovine serum albumin (Roche Diagnostics, Rotkreuz, Switzerland). The signal was detected using an ImageQuant LAS-4010 (GE Healthcare, Chicago, IL). HSV-60 (InvivoGen) was added to cells with Lipofectamine 3000 (Thermo Fisher).

### **Epigenetic regulation**

A chemical library for epigenetics research (containing 80 compounds) was purchased from Sigma-Aldrich (S990043-EPI1). Decitabine, I-BET 726, and LMK-235 were purchased from Selleck (Houston, TX) and dissolved in DMSO. Cells were seeded in a 96-well plate at  $1 \times 10^5$  cells per well, and each compound was added at the indicated concentrations. After incubation for 24 hours, cells were collected and analyzed.

### **Reverse transcription and real-time PCR for IFN- $\beta$ mRNA**

Total RNA was isolated using an RNeasy Mini Kit (Qiagen). PrimeScript RT Master Mix (Takara Bio Inc., Kusatsu, Japan) was used for cDNA synthesis. The samples were run on a ViiA7 Real-Time PCR System (Applied Biosystems). Amplification was performed using SYBR Premix Ex Taq II (Takara Bio Inc.) as follows: 95°C for 30 seconds followed by 40 cycles of 95°C for 5 seconds and 60°C for 30 seconds. All the experiments were performed in triplicate. RPL13A was used as an endogenous control. The  $\Delta\Delta C_t$  method was used to quantify the relative amount of mRNA in each sample in comparison with the control. Primer sequences used were: RPL13A (forward: 5'-TGTTGGACTTTCCACCTG-3', reverse: 5'-AACCCCTTGTTGTGC-3'), IFN- $\beta$  (forward: 5'-CGACACTGTTCTGTGTGCA-3', reverse: 5'-GAAGCACAACAGGAGAGCAA-3')

### **Animal experiments**

Four-week-old female SCID Beige mice were purchased from Charles River Laboratories Japan, Inc. and were used in experiments at five weeks of age. GRANTA-519 or ED-40515(+) cells ( $5 \times 10^6$ ) in a mixture of 50  $\mu$ L of RPMI-1640 without serum and 50  $\mu$ L of Matrigel (BD Biosciences) were implanted subcutaneously into the left flank.<sup>2</sup> When tumors reached about 5 mm in diameter, mice were randomized, and T-01 ( $2 \times 10^5$  or  $1 \times 10^6$  pfu) or mock in 20  $\mu$ L PBS containing 10% glycerol was injected into the tumors on days 0 and 3. The mice were killed when the maximum diameter of tumors exceeded 20 mm. The tumor size was measured using Vernier calipers every 2 or 3 days. The tumor volume was calculated using the formula  $1/2 \times [\text{long axis}] \times [\text{short axis}]^2$ .

Four-week-old female C57BL/6 mice were purchased from Charles River Laboratories Japan, Inc. and were used in experiments at five weeks of age. E.G7-OVA-nectin-1 cells ( $1 \times 10^6$ ) in a mixture of 50  $\mu$ L of RPMI-1640 without serum and 50  $\mu$ L of Matrigel were implanted subcutaneously into the right and left flanks.<sup>2</sup> When tumors reached about 5 mm in diameter, mice were randomized, and T-01 ( $2 \times 10^6$  pfu) or mock in 20  $\mu$ L PBS containing 10% glycerol was injected into the right-side tumors on days 0 and 3. The mice were killed 10 days after the second injection of T-01 or mock, and TILs and spleen cells were isolated. The cells were stained with FITC-conjugated rat anti-mouse CD8 mAb, biotinylated and streptavidin-PE-bound H-2K<sup>b</sup> OVA tetramer or negative (SIY) tetramer (MBL), and 7-aminoactinomycin D (BioLegend). OVA tetramer<sup>+</sup>CD8<sup>+</sup> T cells were detected by flow cytometry.

### Supplemental References

1. ten Dam, G.B., Kurup, S., van de Westerlo, E.M.A., Versteeg, E.M.M., Lindahl, U., Spillmann, D., et al. (2006). 3-O-Sulfated Oligosaccharide Structures Are Recognized by Anti-heparan Sulfate Antibody HS4C3. *J. Biol. Chem.* 281, 4654-4662.
2. Mezencev, R., and McDonald, J.F. (2011). Subcutaneous xenografts of human T-lineage acute lymphoblastic leukemia Jurkat cells in nude mice. *In Vivo* 25, 603-607.